CD274 and neoplasm: However, data from a phase I/II trial indicate that CB-839 is capable of reversing the acquired resistance to PD1/PD-L1 inhibitors in advanced melanoma, NSCLC and renal cell carcinoma, with significant rates of disease stabilizations or tumor regressions [128].